The stock price of Lantern Pharma Inc. (NASDAQ: LTRN), which had a 14.14% gain yesterday and close at $5.49, has witnessed a notable spike, rising 11.11% in pre-market trading to $6.10. The business’s participation in a virtual event today and this spike highlight the market’s favorable perception of the AI-driven cancer treatment discovery and development company.
The company, represented by CEO Mr. Panna Sharma, will be featured in a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference, hosted by HCW. Mr. Sharma’s presentation will highlight RADR, Lantern Pharma’s proprietary AI platform, and its transformative impact on the efficiency and pace of oncology drug development.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Recently, LTRN has achieved significant milestones in the expansion and enhancement of RADR, with data points surpassing 60 billion. This exponential growth in data enables more precise insights into cancer treatment areas that have seen limited progress. Moreover, Lantern Pharma anticipates RADR’s data points to exceed 100 billion this year, enhancing the platform’s ability to guide drug development across various cancer types.
Lantern Pharma plans to further expand RADR’s data through automated processes, leveraging machine learning to collect and curate datasets efficiently. The company expects substantial contributions from immuno-oncology studies and clinical trials, as well as molecular feature extraction from diverse molecules. This data will facilitate robust multi-omic analyses, guiding the utilization of LP-184, LP-284, and similar agents in combination with checkpoint inhibitors.
RADR’s growth has bolstered Lantern Pharma’s capabilities in novel ADC development and predicting combination therapy approaches. Previously, identifying and analyzing new cancer therapies were slow and costly processes lacking real-world correlations. However, RADR has accelerated these processes, potentially halving the traditional drug development timeline of 10 to 12 years. Such advancements not only revolutionize the industry but also hold promise for millions awaiting cancer therapies and cures.
Lantern Pharma’s stock surge reflects investor optimism surrounding its participation in a pivotal virtual event, highlighting the transformative impact of RADR on oncology drug development. With exponential data growth and automated processes, Lantern Pharma is poised to revolutionize cancer therapy development, potentially halving traditional timelines and improving outcomes for patients worldwide.
